AstraZeneca presented new cell therapy research data at the American College of Rheumatology’s ACR2026 meeting, highlighting progress in the field.
Craig Maxwell, Global Head of Cell Therapy at AstraZeneca, shared details about the presentation on LinkedIn. Cell therapy successfully treats certain blood cancers, and researchers now aim to apply these treatments to autoimmune diseases.
“Seeing our cell therapy research presented to the rheumatology community speaks to just how far this field has come and the rapid pace of innovation,” Maxwell said on LinkedIn.
AstraZeneca Pursues Curative Cell Therapy Across Specialties
AstraZeneca focuses on developing cell therapies for oncology, rare diseases, and autoimmune conditions. Company leadership views the recent ACR2026 presentation as a step toward realizing the curative potential of these treatments across multiple medical specialties.
“At AstraZeneca, our ambition is to realise the curative potential of cell therapy across a wide range of diseases spanning oncology, autoimmune and rare disease, and it’s inspiring to see this ambition coming to life!” Maxwell said.
Future Treatment Directions
The medical community continues to explore CAR-T cell therapy applications beyond oncology. Nabil Chehab previously highlighted AstraZeneca’s broader exploration of CAR-T cell therapy for autoimmune diseases and various cancers.
Researchers are evaluating how manufacturing processes and targeted cell delivery can be adapted for non-cancerous immune conditions. Clinical trials are continuing to test these hypotheses in patient populations.
Frequently Asked Questions
What is ACR2026?
ACR2026 is the annual meeting hosted by the American College of Rheumatology where researchers share advancements in rheumatology and immunology.
Tracing its corporate origins back to 1913, AstraZeneca was established when Astra AB was formed by a large group of doctors and apothecaries. The company in its current form was created in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group.
Which diseases are targeted by AstraZeneca’s cell therapy?
AstraZeneca focuses its cell therapy research on oncology, rare diseases, and autoimmune conditions.
Related reading